💊
Lynozyfic
linvoseltamab
Multipel myelom
✅ Autoriseret
✅
Ingen aktive alarmer
Denne medicin har ingen igangværende mangel, sikkerhedsbreve eller tilbagekaldelser.
Hvad det bruges til
Monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
⚠️ Patient sikkerhed
No
Officiel EMA-side
https://www.ema.europa.eu/en/medicines/human/EPAR/lynozyfic